

## Ge Lin (*Curriculum Vitae*)

### Present academic position:

*Professor* School of Biomedical Sciences, The Chinese University of Hong Kong  
*Director* Joint Research Laboratory for Promoting Globalization of Traditional Chinese Medicines between Shanghai Institute of Materia Medica, Chinese Academy of Sciences and The Chinese University of Hong Kong

### Academic qualifications:

Ph.D. College of Pharmacy, University of Saskatchewan, Canada, 1992  
M.Sc. Department of Chemistry, University of Alberta, Canada, 1988  
B.Sc. College of Pharmacy, China Pharmaceutical University, China, 1982

### Previous academic positions held:

2009-present *Professor*, School of Biomedical Sciences, The Chinese University of Hong Kong  
1993-2009 *Professor (2001); Associate Professor (1997); Assistant Professor (1993)*, Department of Pharmacology, The Chinese University of Hong Kong  
1992-1993 *Postdoctoral Fellow*, College of Pharmacy, University of Saskatchewan  
1982-1985 *Assistant Professor*, Department of Processing of Chinese medicines, China Pharmaceutical University, China

### Research interests:

- Toxicology, tumorigenicity, and idiosyncratic adverse effects, in particular drug/natural product metabolism-induced hepatotoxicity
- Pharmacokinetics (absorption, distribution, metabolism and excretion), pharmacology and drug delivery of orthodox drugs and traditional Chinese medicinal (TCM) herbs
- Integrative approach for the study of TCM herbs, including chemical analysis, pharmacology, pharmacokinetics, safety and quality control of TCM herbs
- Herb-drug and herb-herb interactions, in particular synergistic anticancer effects in the combinational therapy of anticancer drugs with TCM herbs

### Research grants awarded since joined The Chinese University of Hong Kong:

- 26 competitive grants as PI (HK\$~22.6 Million)
- 31 Grants as Co-I (HK\$~44,1 Million)

### Previous relevant research work:

I have been working in the fields of chemical analysis, pharmacology, pharmacokinetics, and safety of orthodox drugs, medicinal herbs, and natural products for over 26 years. My research team has a long track record in research of PA-induced liver injury and is one of the leading groups in mechanistic study and development of biomarkers of PA-induced liver injury. Supported by various RGC/GRF and other grants, our laboratory has well-established various methods and models for the investigation of PA-induced acute and chronic liver injury in animals and humans.

**Five most representative publications in the recent five years (\*corresponding author):**

1. M.B. Yang, J.Q. Ruan, H. Gao, N. Li, J. Ma, J. Xue, Y. Ye, **P.P. Fu**, J.Y. Wang and **G. Lin\*** (2017). First evidence of pyrrolizidine alkaloid *N*-oxide-induced hepatic sinusoidal obstruction syndrome in humans. *Archives of Toxicology*. In press. (doi:10.1007/s00204-017-2013-y).
2. N. Li, F. Zhang, W. Lian, H. Wang, J. Zheng\* and **G. Lin\*** (2017). Immunoassay approach for diagnosis of exposure to pyrrolizidine alkaloids. *Journal of Environmental Science and Health, Part C*. **35**, 127-139.
3. Zhu, J. Xue, Q. Xia, **P.P. Fu**, and **G. Lin\*** (2016). The long persistence of pyrrolizidine alkaloid-derived DNA adducts *in vivo*: kinetic study following single and multiple exposures in male ICR mice. *Archives of Toxicology*. **91**, 949-965.
4. L. Zhu, J.Q. Ruan, N. Li, **P.P. Fu**, Y. Ye and **G. Lin\*** (2016). A novel ultra-performance liquid chromatography hyphenated with quadrupole time of flight mass spectrometry method for rapid estimation of total toxic retronecine-type of pyrrolizidine alkaloids in herbs without requiring corresponding standards. *Food Chemistry*. **194**, 1320-1328.
5. J.Q. Ruan, H. Gao, N. Li, J.Y. Xue, J. Chen, C.Q. Ke, Y. Ye, **P.P. Fu**, J. Zheng, J.Y. Wang and **G. Lin\*** (2015). Blood pyrrole-protein adducts – A biomarker of pyrrolizidine alkaloid-induced liver injury in humans. *Journal of Environmental Science and Health, Part C*. **33**, 404-421.

**Five representative publications beyond the recent five-year period with the latest publication entered first:**

1. B. Ma, D. Yang, N. Li and **G. Lin\*** (2011). Effects of structural modification on intestinal absorption and transport mechanism of  $\alpha$ -aminoxy peptides. *Molecular Pharmaceutics*. **8**, 1073-1082.
2. **G. Lin\***, J.Y. Wang, N. Li, M. Li, H. Gao, Y. Ji, F. Zhang, Y. Zhou, Y. Ye, H.X. Xu and J. Zheng (2011). Hepatic sinusoidal obstruction syndrome associated with *Gynura segetum*. *Journal of Hepatology*. **54**, 666-673.
3. R. Yan, N.L. Ko, S. L. Li, Y.K. Tam and **G. Lin\*** (2008). Pharmacokinetics and metabolism of ligustilide, a major bioactive component in Rhizoma Chuanxiong, in the rat. *Drug Metabolism and Disposition*. **36**, 400-408.
4. **G. Lin\***, J. Tang, X.Q. Liu, Y. Jiang and J. Zheng (2007). Deacetylclivorine: a gender-selective metabolite of clivorine formed in female SD rat liver microsomes. *Drug Metabolism and Disposition*. **35**, 607-613.
5. **G. Lin\***, Y.Y. Cui and E.M. Hawes (1998). Microsomal formation of pyrrolic alcohol glutathione conjugate of clivorine: Firm evidence for the formation of pyrrolic metabolites of an otonecine-type pyrrolizidine alkaloid. *Drug Metabolism and Disposition*, **26**, 181-184.

*Due to the limitation of 800-words allowed, detailed information is not provided but available upon request.*